Skip to content
CLNNClene Inc.

Earnings

When Clene Inc. reports, what it reported each quarter, and how the stock took the results.

27 quarters. Mar 31, 2020 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 11, before the open

Thu, Mar 11, 2027in 113 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 10 – 26

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$77.00K
Revenue, change from a year earlier: Q3 2026 +273.3%, Q2 2026 +233.3%, Q1 2026 −81.5%, Q4 2025 −15.4%
Net income
-$9.23M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q3 2025 n/m, Q3 2022 n/m, Q2 2022 n/m

Quarter by quarter

Q3 2026$56.00K+273.3% vs Q3 2025

Latest results

  1. Q3 2026Nov 4, 2026, before the openThe release+10.8%by the close of Nov 4
    Revenue
    $56.00K
    +273.3%
    Net income
    $3.92M
    N/M
    EPS
    $0.05
    N/M
    In October, Clene submitted an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS.
  2. Q2 2026Aug 14, 2026, before the openThe release1.2%by the close of Aug 14
    Revenue
    $90.00K
    +233.3%
    Net income
    -$13.42M
    N/M
    EPS
    —
    —
  3. Q1 2026May 14, 2026, before the openThe release+8.5%by the close of May 14
    Revenue
    $15.00K
    −81.5%
    Net income
    -$8.09M
    N/M
    EPS
    —
    —
  4. Q4 2025Mar 12, 2026, before the openThe release+5.9%by the close of Mar 12
    Revenue
    $77.00K
    −15.4%
    Net income
    -$9.23M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · pre-marketNov 4, 202635 d10-Q$56.00K+273.3%$0.05+10.8%
Q2 2026Jun 30, 2026Aug 14, 2026 · pre-marketAug 14, 202645 d10-Q$90.00K+233.3%—1.2%
Q1 2026Mar 31, 2026May 14, 2026 · pre-marketMay 14, 202644 d10-Q$15.00K−81.5%—+8.5%
FY 2025
Q4 2025derivedDec 31, 2025Mar 12, 2026 · pre-marketMar 17, 202676 d10-K$77.00K−15.4%—+5.9%
Q3 2025Sep 30, 2025Nov 13, 2025 · pre-marketNov 13, 202544 d10-Q$15.00K−82.8%-$0.8526.2%
Q2 2025Jun 30, 2025Aug 14, 2025 · pre-marketAug 14, 202545 d10-Q$27.00K−70.3%—5.1%
Q1 2025Mar 31, 2025May 7, 2025 · pre-marketMay 7, 202537 d10-Q$81.00K+11.0%—8.8%
FY 2024
Q4 2024derivedDec 31, 2024Mar 24, 2025 · pre-marketMar 24, 202583 d10-K$91.00K−46.5%—4.0%
Q3 2024Sep 30, 2024Nov 13, 2024 · pre-marketNov 13, 202444 d10-Q$87.00K−19.4%—19.0%
Q2 2024Jun 30, 2024Aug 7, 2024 · pre-marketAug 7, 202438 d10-Q$91.00K−66.2%—13.9%
Q1 2024Mar 31, 2024May 8, 2024 · pre-marketMay 8, 202438 d10-Q$73.00K−31.8%——
Earlier years, FY 2020 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026034776
10-QAug 14, 2026027828
10-QMay 14, 2026016878
10-KMar 17, 2026008502
10-QNov 13, 2025034613
10-QAug 14, 2025026679
10-QMay 7, 2025014918
10-KMar 24, 2025008956
10-QNov 13, 2024034663
10-QAug 7, 2024025014

Provenance

ProvenanceData status and checks

Clene Inc. · CIK 1822791 · Engraved from SEC EDGAR